The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:1173-1174 September 14, 2006 Number 11
NextNext

Cyclophosphamide in Scleroderma Lung Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Tashkin, D. P.
-PubMed Citation
To the Editor: In their report showing the modest efficacy of oral cyclophosphamide in the management of scleroderma-related interstitial lung disease, Tashkin et al. (June 22 issue)1 do not describe glucocorticoid use among study participants. Patients taking prednisone at a dose of up to 10 mg per day were eligible for inclusion in the investigation. Accordingly, it is not possible to determine whether low-dose glucocorticoids may have contributed to the disease-modifying effects attributed to cyclophosphamide. Glucocorticoids in low2 and medium-low3 doses administered with cyclophosphamide have been reported to improve lung function in patients with scleroderma-related interstitial lung disease. The authors . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.